We are live on
!
Find out more
SFCM
Seven Fleet Capital Management Portfolio holdings
AUM
$318M
This Fund
S&P 500
This Quarter
Est. Return
+21.73%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$318M
AUM Growth
+$170M
(+115%)
Cap. Flow
+$133M
Cap. Flow
% of AUM
41.89%
Top 10 Holdings %
Top 10 Hldgs %
51.26%
Holding
144
New
59
Increased
36
Reduced
17
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Century Therapeutics
IPSC
|
+$6.2M |
| 2 |
Agios Pharmaceuticals
AGIO
|
+$5.04M |
| 3 |
Vaxcyte
PCVX
|
+$4.51M |
| 4 |
Tango Therapeutics
TNGX
|
+$3.99M |
| 5 |
Tyra Biosciences
TYRA
|
+$3.76M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CG Oncology
CGON
|
+$81.6M |
| 2 |
TERN
Terns Pharmaceuticals
TERN
|
+$5.27M |
| 3 |
Exelixis
EXEL
|
+$3.01M |
| 4 |
Cogent Biosciences
COGT
|
+$2.39M |
| 5 |
BLTE
Belite Bio
BLTE
|
+$1.47M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 55.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Traws Pharma
TRAW
$8.83M
| – | – |
-49,260
| Closed | -$55.7K |
|
|
ORKA
127
Oruka Therapeutics
ORKA
$6.93B
| – | – |
-5,240
| Closed | -$159K |
|
|
MBX
128
MBX Biosciences
MBX
$3.23B
| – | – |
-18,200
| Closed | -$574K |
|
Similar funds
SA
KI
CPH
FNWM
MJFG
KC
EC
WA
Seven Fleet Capital Management's Q1 2026 Portfolio in Review
As of Q1 2026, Seven Fleet Capital Management held 144 positions worth $318M, up 115% from $148M the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Seven Fleet Capital Management deployed $133M of net new capital in Q1 2026, opening 59 new positions and adding to 36 existing holdings. Its largest new stake was Century Therapeutics: 2,947,826 shares worth $6.66M.
By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 100% a quarter earlier.
On the sell side, the largest reduction was CG Oncology, an estimated $81.6M trimmed.
- Seven Fleet Capital Management's largest Q1 2026 buy was Century Therapeutics: 2,947,826 shares worth $6.66M.
- Seven Fleet Capital Management added most to Agios Pharmaceuticals in Q1 2026, an estimated $5.04M increase.
- Seven Fleet Capital Management's biggest Q1 2026 reduction was CG Oncology, cutting an estimated $81.6M.
- Seven Fleet Capital Management fully exited Terns Pharmaceuticals in Q1 2026, selling an estimated $5.27M.
- Seven Fleet Capital Management's ten largest holdings make up 51% of its $318M portfolio in Q1 2026.
- Seven Fleet Capital Management opened 59 new positions and closed 29 in Q1 2026.
- Seven Fleet Capital Management's portfolio value rose 115% quarter-over-quarter to $318M.
Based on Seven Fleet Capital Management's 13F filing for Q1 2026, filed 15 May 2026.